The lifetime distribution of the incremental societal costs of autism

被引:355
作者
Ganz, Michael L.
机构
[1] ABT Associates Inc, Lexington, MA 02421 USA
[2] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
来源
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE | 2007年 / 161卷 / 04期
关键词
D O I
10.1001/archpedi.161.4.343
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective: To describe the age-specific and lifetime incremental societal costs of autism in the United States. Design: Estimates of use and costs of direct medical and nonmedical care were obtained from a literature review and database analysis. A human capital approach was used to estimate lost productivity. These costs were projected across the life span, and discounted incremental age-specific costs were computed. Setting: United States. Participants: Hypothetical incident autism cohort born in 2000 and diagnosed in 2003. Main Outcome Measures: Discounted per capita incremental societal costs. Results: The lifetime per capita incremental societal cost of autism is $3.2 million. Lost productivity and adult care are the largest components of costs. The distribution of costs over the life span varies by cost category. Conclusions: Although autism is typically thought of as a disorder of childhood, its costs can be felt well into adulthood. The substantial costs resulting from adult care and lost productivity of both individuals with autism and their parents have important implications for those aging members of the baby boom generation approaching retirement, including large financial burdens affecting not only those families but also potentially society in general. These results may imply that physicians and other care professionals should consider recommending that parents of children with autism seek financial counseling to help plan for the transition into adulthood.
引用
收藏
页码:343 / E5
页数:11
相关论文
共 57 条
[1]   The lifetime distribution of health care costs [J].
Alemayehu, B ;
Warner, KE .
HEALTH SERVICES RESEARCH, 2004, 39 (03) :627-642
[2]   PSYCHOTROPIC AND ANTICONVULSANT DRUGS IN SUBJECTS WITH AUTISM - PREVALENCE AND PATTERNS OF USE [J].
AMAN, MG ;
VANBOURGONDIEN, ME ;
WOLFORD, PL ;
SARPHARE, G .
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1995, 34 (12) :1672-1681
[3]   Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio [J].
Aman, MG ;
Lam, KSL ;
Collier-Crespin, A .
JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, 2003, 33 (05) :527-534
[4]  
[Anonymous], BUDG EC OUTL UPD
[5]  
[Anonymous], 1924, STAT ABSTR US
[6]  
[Anonymous], MED EXP PAN SURV
[7]  
[Anonymous], STATE SPECIAL ED F 2
[8]  
Birenbaum A., 1990, HLTH CARE FINANCING
[9]  
*BOARD GOV FED RES, FOR EXCH RAT HIST DA
[10]  
*BUR LAB STAT, 2004, OCC OUTL HDB 2004 05